BLUEJET

As part of the struggling CDMO sector, Blue Jet Healthcare has experienced a sharp 60% fall from its 52-week high. Its Q3 FY26 results were particularly dismal, with revenue down 39% and IBITA plunging 62%. Like its peers, it's grappling with client inventory destocking and market cautiousness due to the Biocure Act and the gradual shift towards 'China Plus One' strategies. These are significant headwinds, implying substantial near-term growth concerns and a tough road ahead for shareholders.